Today: 19 April 2026
DroneShield share price slides 7.5% as ASX filing flags possible employee selling
30 January 2026
1 min read

DroneShield share price slides 7.5% as ASX filing flags possible employee selling

Sydney, Jan 30, 2026, 17:29 AEDT — After-hours

  • After the Sydney close, DroneShield slipped 7.5%, finishing at A$3.32.
  • The counter-drone company filed to list 4.565 million new shares, all stemming from exercised performance options.
  • Traders are eyeing additional stock overhang ahead of the company’s late-February earnings report.

Shares of DroneShield Limited tumbled on Friday following the company’s announcement that it has filed to issue millions of new shares, fueling concerns over potential near-term selling pressure.

The stock ended at A$3.32, slipping 7.5% from A$3.59, after fluctuating between A$3.26 and A$3.52 during the session.

The key point now: this new stock stems from employee awards, with the company warning some holders might sell. Given how volatile the share has been lately, even a modest increase in supply could shift the price.

In Australia, “performance options” are equity awards that turn into ordinary shares once specific conditions are fulfilled. Applying for “quotation” is what allows those shares to be listed and traded on the ASX.

DroneShield lodged an Appendix 2A on Thursday, seeking quotation for 4,565,000 fully paid ordinary shares. These shares stem from the exercise of performance options that vest in November 2025 and January 2026. The company noted the shares were issued for nil consideration and carry no sale restrictions, expecting “a number of employees” to sell. Company Announcements

The new stock makes up only about half a percent of DroneShield’s total issued capital, according to the filing. Still, it arrives amid heightened market sensitivity to insider and employee sales.

DroneShield provides systems designed to detect and neutralize unauthorized drones, offering both hardware and software solutions aimed at military and security clients, the company’s website states.

After the market closed, the chatter shifted to who’s unloading shares and why. CEO Oleg Vornik told The Nightly he sold stock to cover a hefty tax bill on vested options, noting “half of it was tax.” Meanwhile, short seller Plato Long Short Fund flagged the insider selling as a “governance red flag,” according to the report. The Nightly

Investors face the risk that ongoing option exercises and employee sales will steadily flood the market with shares, dampening any rally. When volumes dry up, price swings can accelerate sharply, going either way.

As the Sydney session kicks off on Monday, traders will be watching to see if the stock holds around A$3.30 or if selling pressure pushes it below recent lows. They’ll also keep an eye out for any new ASX notices related to option conversions or director dealings.

Looking ahead, the company’s next major event is its earnings report, scheduled for Feb. 24, as noted on the market calendar.

Stock Market Today

  • 2 TSX Stocks Under $100 with Strong Upside Potential
    April 18, 2026, 9:56 PM EDT. CES Energy (TSX:CEU) and Bird Construction are two TSX-listed stocks priced below $100 that offer significant growth potential. CES Energy provides consumable chemical solutions to oil and gas producers, benefiting from rising service intensity and demand for advanced chemical treatments. Despite softer drilling activity, CES's revenue growth remains robust, supported by its asset-light model and strategic acquisitions. Macro trends like growing global energy demand and LNG infrastructure expansion further boost its outlook. Bird Construction, also trading under $100, stands out for its presence in the construction sector, which benefits from infrastructure spending and urban development. Both companies show disciplined capital allocation and resilient revenue drivers, making them attractive for investors seeking accessible entry points and potential capital appreciation on the TSX.

Latest article

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

18 April 2026
Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
Bellevue Gold share price slides 5% as gold tumbles from record highs — what to watch next week
Previous Story

Bellevue Gold share price slides 5% as gold tumbles from record highs — what to watch next week

Keppel share price drops as Singapore investors weigh SAF project ahead of Feb 5 earnings
Next Story

Keppel share price drops as Singapore investors weigh SAF project ahead of Feb 5 earnings

Go toTop